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Introduction {#sec1}
============

Establishment and maintenance of the adult hematopoietic system requires the generation of hematopoietic stem cells (HSCs) from a unique endothelial cell (hemogenic) in the aorta-gonad-mesonephros (AGM) region of the mammalian embryo ([@bib14]). HSCs develop in clusters that bud off from hemogenic endothelium ([@bib5], [@bib6]), a process termed endothelial to hematopoietic transition (EHT). HSCs migrate to and colonize the fetal liver and, subsequently, the bone marrow ([@bib50]). Whereas major efforts have focused on defining regulatory proteins/networks governing EHT, many questions remain unanswered regarding the molecular constituents and mechanisms.

Master regulatory transcription factors co-localize at *cis* elements of target genes in hematopoietic stem and progenitor cells (HSPCs) to establish genetic networks that control hematopoiesis ([@bib4], [@bib15], [@bib44], [@bib62], [@bib67], [@bib68], [@bib69]). The combinatorial mechanisms operating in hemogenic endothelium, and the relationship between mechanisms governing EHT and HSC multi-potency, are unclear. A shared component of the mechanisms involves the transcription factor GATA-2, which is required for definitive hematopoiesis ([@bib64]). GATA-2 functions in hemogenic endothelium to induce EHT and regulates HSC function ([@bib11], [@bib16], [@bib29], [@bib38], [@bib54]).

Since GATA-2 induces EHT, it is instructive to consider factors/signals upstream of GATA-2. Deletion of a *cis* element 9.5 kb downstream of the *Gata2* promoter (+9.5) in mice decreased *Gata2* expression in AGM hemogenic endothelium, deregulated genes encoding positive regulators of hematopoiesis, and abrogated EHT ([@bib16]). Deletion of a *cis* element 77 kb upstream of the promoter (−77) reduced *Gata2* expression in myelo-erythroid progenitors and impaired progenitor function without affecting EHT ([@bib30]). The defective HSC generator of +9.5^−/−^ embryos depleted HSPCs in the fetal liver and caused lethality at embryonic day 13--14 (E13--14) ([@bib29]). Since the +9.5 controls *Gata2* expression and EHT ([@bib16], [@bib24]), and GATA-2 occupies the +9.5 ([@bib15], [@bib19]), one aspect of the +9.5 mechanism involves GATA-2-mediated positive autoregulation. Factors implicated upstream of GATA-2 include bone morphogenetic protein 4 ([@bib40], [@bib41]), Notch signaling ([@bib20], [@bib53]), the Ets factor Etv2 ([@bib39]), and the methylcytosine dioxygenases Tet2/Tet3 ([@bib37]).

The *Gata2* +9.5 site regulates a large gene cohort in hemogenic endothelium, and these genes do not parse into a single pathway ([@bib16]). The genes include *Runx1*, *Lyl1*, and *Mpl*, positive mediators of HSC generation and/or function. The identification of vital constituents of the +9.5-dependent genetic network will reveal how a *cis* element triggers EHT. As GATA-2 lacks features that can be leveraged for drug binding, identifying +9.5 network components will reveal strategies to promote HSC generation/function for transplantation and inhibit leukemia cell proliferation and survival.

The most common targets for drugs approved by the Food and Drug Administration are GPCRs ([@bib55]). The GPCR family consists of 341 non-olfactory receptors classified as rhodopsin, secretin, glutamate, adhesion, and frizzled/taste2, based on sequence homology ([@bib33]). CXCR4, a rhodopsin-like GPCR, recognizes SDF-1/CXCL-12 and controls HSPC survival, proliferation, migration, and engraftment ([@bib7]). CXCR4 antagonists are used as mobilizing agents for stem cell transplantation. The prostaglandin PGE2, which functions through a group of related GPCRs ([@bib60]), expands HSPCs ([@bib17], [@bib23], [@bib49]). We described +9.5-mediated upregulation of *Gpr56* expression ([@bib16]). Loss-of-function analyses indicated that GPR56 promotes EHT ([@bib59]) and contributes to HSC maintenance ([@bib56]). Galpha(s)-mediated signaling controls HSPC engraftment of bone marrow ([@bib1]).

By profiling expression of the GPCR cohort in the AGM, we discovered a subset of GATA-2-regulated GPCRs and a GATA-2- and GATA-1-regulated cohort, including GPR65, which suppresses AGM hematopoiesis. The +9.5 site, and its regulated protein GATA-2, which positively regulate hematopoiesis, upregulated *Gpr65* encoding a negative regulator of hematopoiesis. These results provide evidence for a GATA factor-GPCR type I incoherent feedforward loop as a vital component of the genetic network that controls HSPC generation and function.

Results {#sec2}
=======

GATA-2 Expression in +9.5^−/−^ AGM Rescues Hematopoiesis {#sec2.1}
--------------------------------------------------------

Deletion of the +9.5 site reduced *Gata2* expression in AGM hemogenic endothelium and abrogated EHT ([@bib16]) ([Figure 1](#fig1){ref-type="fig"}A). These results suggest that factors/signals conferring +9.5 activity control *Gata2* expression, which promotes EHT. In principle, the +9.5 might regulate other genes in *cis* or in *trans* that control EHT. To determine whether the HSC generation defect of +9.5^−/−^ AGM results from insufficient GATA-2 production, we tested whether GATA-2 expression rescues the defect. E11.5 mouse embryo AGMs were infected with GATA-2-expressing retrovirus ([Figure 1](#fig1){ref-type="fig"}A). After 96 hr of explant culture, we quantitated endothelial and hematopoietic cell populations in infected (GFP^+^) cells by flow cytometry using CD31 and c-KIT surface markers. The infection efficiency was similar among the three conditions (+9.5^+/+^-empty vector, +9.5^−/−^-empty vector, +9.5^−/−^-GATA-2), as indicated by the indistinguishable percentage of GFP^+^ live cells ([Figure 1](#fig1){ref-type="fig"}B). GATA-2 expression restored *Gata2* mRNA to the wild-type level in CD31^+^c-KIT^−^ endothelial and CD31^+^c-KIT^+^ hematopoietic cells ([Figure 1](#fig1){ref-type="fig"}C), and rescued both populations ([Figures 1](#fig1){ref-type="fig"}D and 1E). Since the infected cells express GFP, the percentage of GFP^+^ cells in each population increased in +9.5^−/−^ AGM infected with GATA-2-expressing retrovirus ([Figure 1](#fig1){ref-type="fig"}F). However, retroviral-mediated GATA-2 expression did not rescue CD31^+^c-KIT^−^ endothelial and CD31^+^c-KIT^+^ hematopoietic cell populations in the GFP^−^ cells ([Figure S1](#mmc1){ref-type="supplementary-material"}). Thus, the +9.5^−/−^ AGM hematopoiesis defect resulted from insufficient GATA-2 production, is associated with reduced CD31^+^c-KIT^−^ endothelial cells, and can be rectified by restoring GATA-2.

To assess whether the GATA-2-rescued CD31^+^c-KIT^+^ hematopoietic cells are functional, we measured their capacity to generate myelo-erythroid colonies in a colony-forming unit (CFU) assay. After culturing retroviral-infected AGMs for 96 hr, GFP^+^ CD31^+^c-KIT^+^ hematopoietic cells were isolated by fluorescence-activated cell sorting (FACS) and assayed for their capacity to generate BFU-E (erythroid burst-forming units), CFU-GM (granulocyte, macrophage), and CFU-GEMM (granulocyte, erythrocyte, monocyte/macrophage, megakaryocyte) colonies. Whereas +9.5^−/−^ AGM failed to generate CFUs, GATA-2 expression in the +9.5^−/−^ AGM induced CFUs comparable with +9.5^+/+^ AGM ([Figure 2](#fig2){ref-type="fig"}A). Quantification of colony types revealed comparable numbers of rescued CFU-GM colonies in comparison with wild-type AGM ([Figure 2](#fig2){ref-type="fig"}B). GATA-2 expression induced BFU-E and CFU-GEMM colonies ([Figure 2](#fig2){ref-type="fig"}B). Colonies derived from wild-type and rescued samples were morphologically indistinguishable ([Figure 2](#fig2){ref-type="fig"}C). Wright-Giemsa staining of cells from colonies revealed normal myeloid and erythroid cell generation from the GATA-2-expressing +9.5^−/−^ AGM ([Figure 2](#fig2){ref-type="fig"}D). The GATA-2-induced CD31^+^c-KIT^+^ hematopoietic cells exhibited qualitatively and quantitatively normal activity.

Global GPCR Analysis in the AGM: Discovery of a GATA Factor-Regulated GPCR Cohort {#sec2.2}
---------------------------------------------------------------------------------

The +9.5 site confers *Gata2* expression and establishes a genetic network involving known HSC regulators and genes not implicated in hematopoiesis ([@bib16]). To discover vital constituents of the network, especially those with potential for modulation by small molecules/drugs, we systematically analyzed the expression pattern of non-olfactory GPCRs ([Figure 3](#fig3){ref-type="fig"}A). The human genome encodes greater than 800 GPCRs, which are categorized into rhodopsin, secretin, glutamate, adhesion and frizzled/taste2 families based on sequence homology; 341 are distinct from the olfactory and taste GPCRs ([@bib33], [@bib55]). Using our AGM RNA-sequencing (RNA-seq) data ([@bib16]), we parsed AGM-expressed GPCRs into the canonical categories: secretin, 5% (15); adhesion, 7% (22); glutamate, 5% (15); frizzled/taste2, 6% (20); and rhodopsin, 70% (221) ([Figure 3](#fig3){ref-type="fig"}B).

To discover GPCRs that control HSC generation and/or activity, we evaluated GPCR expression in the AGM. Of the 314 GPCRs annotated by RNA-seq, 85 were expressed at \>5 transcripts per million ([Figure 3](#fig3){ref-type="fig"}C), a level that can be validated with high frequency by real-time RT-PCR. Of the 85 GPCRs, 20 were downregulated in the +9.5^−/−^ AGM versus +9.5^+/+^ AGM ([Figure 3](#fig3){ref-type="fig"}D), indicating GATA-2-regulation. Using our previous microarray dataset (untreated or β-estradiol-treated G1E-ER-GATA-1 erythroid precursor cells) ([@bib12]), we found that four of the 20 GATA-2-regulated GPCRs were GATA-1-regulated ([Figure 3](#fig3){ref-type="fig"}D). Our strategy refined the 314 non-olfactory, AGM-expressed GPCRs to yield *Adora3*, *Gpr65*, *Ltb4r1*, and *P2ry1*, which are GATA-2- and GATA-1-regulated.

A GATA Factor-GPCR Incoherent Feedforward Loop Suppresses AGM Hematopoiesis {#sec2.3}
---------------------------------------------------------------------------

As shared gene expression patterns can infer functional interconnectivity, we compared *Adora3*, *Gpr65*, *Ltb4r1*, *P2ry1*, and *Gata2* expression patterns in mouse cells and tissues. Only *Gpr65* resembled *Gata2*, both being expressed in HSPCs and mast cells ([Figure S2](#mmc1){ref-type="supplementary-material"}) (<http://biogps.org>). As GATA-1 represses *Gata2* during erythroid maturation via a GATA switch, *Gata2* expression declines upon erythroid maturation. Mining the Erythron Database, which provides transcriptomics data during erythroid precursor cell maturation into erythrocytes ([@bib32]), revealed *Gata2* and *Gpr65* repression upon erythroid differentiation. *Gpr65* was the only one of the four GPCR genes to have a *Gata2*-like expression pattern ([Figure 3](#fig3){ref-type="fig"}E). To further compare expression patterns, we quantitated *Gata2* and *Gpr65* mRNA in G1E-ER-GATA-1 cells treated with β-estradiol to induce erythroid maturation and in FACS-sorted R1, R2, R3, and R4/5 fetal liver cell populations. *Gpr65* and *Gata2* were repressed during erythroid maturation ([Figures 3](#fig3){ref-type="fig"}F and 3G). These correlations are consistent with GATA-2 upregulating *Gpr65* expression in the AGM and may point to a functional link between GATA-2 and GPR65. Chromatin immunoprecipitation (ChIP)-sequencing analysis in human ([Figure 3](#fig3){ref-type="fig"}H) and mouse ([Figure 3](#fig3){ref-type="fig"}I) cells revealed GATA-2 occupancy at *Gpr65*, suggesting that GATA-2 directly regulates *Gpr65* transcription. Comparison of +9.5^+/+^ and +9.5^−/−^ AGM revealed that reduced *Gata2* expression in the +9.5^−/−^ AGM decreased *Gpr65* expression, and *Gpr65* expression was undetectable in the yolk sac ([Figure 3](#fig3){ref-type="fig"}J). Previously, we demonstrated that GATA-2 expression in mouse aortic endothelial cells increases transcription of certain GATA-2 target genes ([@bib31]). In this system, GATA-2 increased *Gpr65* expression ([Figure 3](#fig3){ref-type="fig"}K), indicating that GATA-2 regulates *Gpr65* expression in multiple contexts. To analyze the *Gpr65* expression pattern in distinct cell types within the AGM, we mined RNA-seq data obtained with FACS-sorted endothelial cells, hemogenic endothelial cells, hematopoietic cells, and HSCs from the AGM ([@bib59]). This analysis revealed that *Gpr65* is detectable in all cell types, and the levels are lower in HSCs ([Figure 3](#fig3){ref-type="fig"}L).

To test whether GPR65 controls hematopoiesis in the AGM, we conducted a loss-of-function analysis using a *Gpr65* short hairpin RNA (shRNA) retrovirus. E11.5 AGMs were infected, and after culturing for 96 hr hematopoietic cell populations were quantitated by flow cytometry. Quantitation of GFP^+^ live cells indicated that control shRNA (shLuc) and sh*Gpr65* retroviruses had an indistinguishable infection efficiency ([Figures 4](#fig4){ref-type="fig"}A and 4B). *Gpr65* knockdown reduced *Gpr65* mRNA by 60%--70% ([Figure 4](#fig4){ref-type="fig"}C). While downregulating *Gpr65* did not alter CD31^+^c-KIT^+^ hematopoietic cells ([Figures 4](#fig4){ref-type="fig"}A and 4D), it increased CD31^+^c-KIT^+^SCA1^+^ HSC-containing, multipotent hematopoietic cells ([Figures 4](#fig4){ref-type="fig"}A and 4E). Retroviral-mediated *Gpr65* shRNA expression did not alter CD31^+^c-KIT^+^ hematopoietic cells and CD31^+^c-KIT^+^SCA1^+^ HSC-containing cells in GFP^−^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}). These results indicate that GPR65 suppresses hematopoiesis in the AGM.

To assess whether *Gpr65* activity to suppress hematopoiesis operates in other systems, we used a morpholino (MO) targeting the *Gpr65* translation start site (*Gpr65*\_ATG MO) to reduce *Gpr65* expression in zebrafish embryos. The *Gpr65*\_ATG MO was injected into 1-cell stage embryos, which were analyzed for expression of the HSPC markers *Runx1/cmyb* using in situ hybridization (ISH) at 36 hr post-fertilization. The *Gpr65*\_ATG MO dose-dependently increased expression of the HSPC markers *Runx1/cmyb* in the embryos ([Figures 4](#fig4){ref-type="fig"}F and 4G). A second MO, which blocks *Gpr65* splicing (*Gpr65*\_SP MO), yielded an identical result; *Gpr65* downregulation induced expression of the HSPC markers *Runx1/cmyb* ([Figure 4](#fig4){ref-type="fig"}G). Thus, GPR65 suppresses hematopoiesis in mouse and zebrafish embryos.

shRNA and MO-based loss-of-function strategies may be confounded by off-target effects. As an alternative strategy we used a GPR65 antagonist, the lysosphingolipid galactosylsphingosine (psychosine). Psychosine was initially proposed to be a GPR65 agonist, based on the GPR65 requirement for psychosine-induced multi-nuclear cell formation ([@bib26]). Subsequently, it was demonstrated that GPR65 is a proton-sensing receptor and that psychosine antagonizes GPR65 ([@bib51], [@bib61], [@bib65]). We treated E11.5 AGMs with vehicle or psychosine, and after 96 hr, hematopoietic cells were quantitated by flow cytometry. While psychosine did not alter CD31^+^c-KIT^+^ cells ([Figures 5](#fig5){ref-type="fig"}A and 5B), it increased the CD31^+^c-KIT^+^SCA1^+^ cell population, which is known to contain multipotent hematopoietic precursors ([Figures 5](#fig5){ref-type="fig"}A and 5C). In aggregate, the mouse and zebrafish studies indicate that GPR65 is an endogenous suppressor of hematopoiesis.

GPR65 Establishes Repressive Chromatin and Disrupts an Activating Complex on a *cis* Element Required for *Gata2* Transcription {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------

To elucidate the mechanism underlying GPR65 suppression of hematopoiesis, we considered whether GPR65 might downregulate key regulators of HSC generation/activity. After knocking down GPR65, we isolated infected CD31^+^c-KIT^−^ endothelial cells that give rise to HSCs. Downregulating *Gpr65* mRNA by 60%--70% increased *Gata2* mRNA 2.9-fold (p = 0.03) and its downstream target *Runx1* mRNA 2.9-fold (p = 0.04) ([Figure 5](#fig5){ref-type="fig"}D). The knockdown elevated *Gata2* primary transcripts 3.9-fold (p = 0.04) ([Figure 5](#fig5){ref-type="fig"}E), indicating that GPR65 suppresses *Gata2* transcription.

To determine whether GPR65 regulates *Gata2* expression in zebrafish, we analyzed *Gata2* expression using ISH at 36 hr post-fertilization. Zebrafish have two *Gata2* homologs; *Gata2b* is enriched in hemogenic endothelium and regulates HSPC emergence ([@bib8]). Whereas the majority of uninjected embryos exhibited broad staining in the AGM, there was no clear linear zone enriched in hemogenic endothelium. However, *Gpr65*\_ATG MO-injected embryos exhibited the linear zone ([Figure S4](#mmc1){ref-type="supplementary-material"}), suggesting that GPR65 suppresses *Gata2* expression in zebrafish embryos. Given that GATA-2 promotes HSC emergence in the AGM and regulates HSC activity ([@bib11], [@bib16]), we propose that GPR65 suppresses hematopoiesis by limiting *Gata2* expression and GATA-2 levels.

As *Gpr65* is expressed in AGM endothelium and HSPCs, we asked whether GPR65 represses *Gata2* expression in other contexts. Fetal liver hematopoietic precursors express *Gata2*, and as GATA-1 rises upon erythroid maturation, *Gata2* is repressed ([@bib45]). We isolated Lin^−^ hematopoietic precursors from E14.5 fetal livers ([@bib45]) and tested whether reducing *Gpr65* expression with the *Gpr65* shRNA retrovirus alters *Gata2* expression. Cells were expanded for 72 hr to increase HSPCs, while suppressing differentiation. Downregulating *Gpr65* increased the proerythroblast-enriched R2 population 1.9-fold (p = 0.0002) and reduced the R3 population (early and late basophilic erythroblasts) 1.6-fold (p = 0.0003) ([Figure 6](#fig6){ref-type="fig"}A). Increased R2 cells, concomitant with reduced R3 cells, suggests that GPR65 promotes erythroid maturation. Downregulating *Gpr65* mRNA by 70%--80%, which lowered GPR65 protein by 50%, increased *Gata2* mRNA and primary transcripts 2.4 (p = 3.65 × 10^−6^) and 2.8-fold (p = 0.014), respectively ([Figures 6](#fig6){ref-type="fig"}B and 6C). Western blot analysis of fetal liver cells revealed that reducing GPR65 expression upregulated GATA-2 ([Figure 6](#fig6){ref-type="fig"}D). Increased GATA-2 selectively elevated GATA-2 target gene expression ([Figure 6](#fig6){ref-type="fig"}E). To test whether increased *Gata2* expression reflected a change in cellularity, we used FACS to isolate the GATA-2-expressing R2 population and compared gene expression in control and knockdown R2 cells. *Gpr65* knockdown upregulated *Gata2* mRNA 2.3-fold (p = 0.02), primary transcript 4.8-fold (p = 0.01), GATA-2 protein, and GATA-2 target genes in FACS-sorted R2 cells ([Figures 6](#fig6){ref-type="fig"}F--6I). These results indicate that GPR65 represses *Gata2* in the AGM and fetal liver. Since GATA-1 needs to repress *Gata2* transcription early in erythroid maturation, upregulated *Gata2* expression caused by the *Gpr65* knockdown would be expected to increase immature R2 cells as observed ([Figure 6](#fig6){ref-type="fig"}A).

The +9.5 enhances *Gata2* expression in the AGM and fetal liver ([@bib16], [@bib29], [@bib57]). Deleting the +9.5 abrogated HSC generation in the AGM ([@bib16]) and disrupted establishment of the HSPC compartment in the fetal liver ([@bib29]). To determine whether increased *Gata2* transcription upon *Gpr65* knockdown requires the +9.5, we isolated Lin^−^ HSPCs from E14.5 + 9.5^+/−^ fetal livers and infected cells with *Gpr65* shRNA retrovirus. After 72 hr of expansion culture, allele-specific primers were used to quantitate primary transcripts from wild-type and mutant 9.5 alleles in fetal liver cells and FACS-purified R2 cells ([Figure 6](#fig6){ref-type="fig"}J). *Gpr65* knockdown upregulated *Gata2* primary transcripts from the wild-type, but not the +9.5 mutant, allele ([Figure 6](#fig6){ref-type="fig"}J), demonstrating importance of the +9.5 for *Gata2* transcription.

Previously, we demonstrated that SetD8, the enzyme that monomethylates H4K20 ([@bib3]), represses *Gata2* expression via the +9.5 site ([@bib13]). We tested the relevance of this mechanism to GPR65-mediated *Gata2* repression. We conducted quantitative ChIP analysis for H4K20me1 in fetal liver cells (control or *Gpr65* knockdown) after culturing for 72 hr. Downregulating *Gpr65* did not alter the SetD8 mRNA level ([Figure 6](#fig6){ref-type="fig"}K). *Gpr65* downregulation reduced H4K20me1 at the +9.5 site (p = 0.002) and at sites 480 bp upstream (p = 0.002), 466 bp downstream (p = 0.006), and 880 bp downstream (p = 0.02) of the +9.5 site ([Figure 6](#fig6){ref-type="fig"}K). H4K20me1 was unaltered at the repressed muscle-specific *MyoD* promoter and the constitutively active *Eif3k* promoter. These results support a mechanism in which GPR65 represses *Gata2* by increasing a repressive chromatin mark at the +9.5 site. The basic helix-loop-helix transcription factor Scl/TAL1 activates *Gata2* transcription through the +9.5 site, and Scl1/TAL1 chromatin occupancy is reduced at the +9.5 site during GATA-1-mediated *Gata2* repression ([@bib57]). As *Gpr65* downregulation decreased H4K20me1 at the +9.5 site, this alteration may generate chromatin that is more accessible to cognate binding factors. To determine whether GPR65 alters GATA-1 and Scl/TAL1 occupancy, we quantitated GATA-1 and Scl/TAL1 occupancy at the +9.5 site in fetal liver cells infected with control shRNA or *Gpr65* shRNA-expressing retrovirus. While knocking down *Gpr65* did not alter GATA-1 occupancy at the +9.5, the knockdown increased Scl/TAL1 occupancy at the +9.5 1.6-fold (p = 0.02) but not at other target loci (*Lyl1* and *Kit*) ([Figures 6](#fig6){ref-type="fig"}K and [S5](#mmc1){ref-type="supplementary-material"}). These results suggest that GPR65 represses *Gata2* by establishing repressive chromatin that limits Scl/TAL1 occupancy at the +9.5 site ([Figure 6](#fig6){ref-type="fig"}L).

Discussion {#sec3}
==========

Genetic networks orchestrating stem and progenitor cell transitions can be deconstructed into regulatory modules termed network motifs ([@bib2], [@bib58]). Whereas major progress has been made to identify individual genes controlling hematopoiesis ([@bib16], [@bib21], [@bib34], [@bib36], [@bib47], [@bib59]), many questions remain unanswered regarding how the genes form network motifs, how the network motifs amalgamate into circuitry, and whether the circuitry has an inherent plasticity and undergoes remodeling in states of altered hematopoiesis such as stress, aging, and malignancy.

Since the GATA-2-dependent genetic network promotes hematopoiesis ([@bib16], [@bib59]), it is reasonable to infer that GATA-2-induced factors are positive mediators of key steps, including EHT, HSPC self-renewal, and differentiation. In erythroid cells, GATA-1 activates heme biosynthetic genes, globin subunits, and constituents of the red cell cytoskeleton ([@bib9], [@bib15], [@bib66], [@bib69]), all required for erythroid maturation. Moreover, GATA-1 represses *Gata2*, *Lyl1*, and *Kit* ([@bib18], [@bib28], [@bib48]), to enable erythroid maturation. GATA-2 activates *Kit* ([@bib27]), an essential regulator of HSPCs ([@bib22], [@bib25]), consistent with GATA-2 promoting HSPC genesis and function.

Using a coupled bioinformatics-experimental strategy, we analyzed the large GPCR gene family to discover GATA-2-induced GPCRs that promote HSPC transitions. This analysis led to the surprising finding that GATA-2 activates *Gpr65* expression, which suppresses hematopoiesis via negative feedback on *Gata2*. This negative feedback mechanism conforms to a type I incoherent feedforward loop ([@bib43]), which is defined as an input (GATA-2) that elicits an output (EHT or hematopoiesis) through positive (increased *Gpr65* expression) and negative (GPR65 suppression of hematopoiesis) paths. Type I incoherent feedforward loops shape the dynamics of a mechanism, with the feedforward loop conferring a pulse of activity to accelerate the reaction ([@bib43]). Since the constituents and network motifs governing HSPC transitions are still being identified, the dynamics of steps in these transitions are largely unexplored. The mechanism of GPR65-mediated *Gata2* repression involved elevation of a repressive histone mark, H4K20me1, linked to reduced occupancy by the activator Scl/TAL1. GPR65 might directly target chromatin to restrict Scl/TAL1 occupancy or might reduce Scl/TAL1 occupancy prior to chromatin modification. Regardless of the order of events, our analysis established a GATA factor-GPCR-dependent type I incoherent feedforward loop that suppresses, rather than promotes hematopoiesis.

*Gpr65*, or T cell death-associated gene 8 (*Tdag8*), is a proton/acid-activated GPCR ([@bib10], [@bib65]). Whereas GPR65 had not been linked to HSPC transitions, it was reported to be a pro-apoptotic factor in glucocorticoid-induced lymphocyte apoptosis ([@bib42]) and to regulate cytokine production from macrophages ([@bib46]). Targeted deletion of *Gpr65* revealed it was dispensable for glucocorticoid-induced thymocyte apoptosis ([@bib52]). These results were suggested to reflect redundancy with related pH-sensing GPCRs, which would create an obstacle to dissect *Gpr65* function in vivo. Although the impact of the pH-sensing mechanism to GATA-2 function in the AGM and fetal liver is unclear, the endogenous GPR65 antagonist psychosine resembled *Gpr65* shRNA in upregulating *Gata2* expression and hematopoiesis.

As GPR65 suppressed HSPC generation from mouse AGM explants, it is instructive to consider the consequences of ablating this mechanism in vivo. Abrogation of the mechanism would promote HSPC genesis and function. Since ablating *Gpr65* would be expected to increase HSPCs, evaluating the role of the GATA-2-GPR65 circuit in vivo will require a careful quantitative analysis. Considerations of type I incoherent feedforward loops ([@bib2], [@bib43]) would infer an alteration of the dynamics of specific steps of hematopoiesis, which might not be evident from steady-state analyses. It is attractive to propose that this suppressive mechanism is vital when the demand for hematopoiesis increases, e.g. during stress, since an unopposed increase could yield deleterious blood cell elevations.

In summary, we discovered that GATA-2 activity to promote hematopoiesis involves induction of both positive and negative mediators, the balance of which establishes the physiological output. Based on the GPR65 pH-sensing function, it will be crucial to analyze the pH microenvironment of the AGM and other sites of hematopoiesis and to establish the role of GPR65 as a mediator of pH-dependent HSPC transitions.

Experimental Procedures {#sec4}
=======================

Mice and Embryo Generation {#sec4.1}
--------------------------

*Gata2* +9.5-mutant mice were described by [@bib29]. Pregnant females were euthanized with CO~2~, and freshly isolated embryos were transferred into cold PBS for dissection. Animal experiments were carried out with ethical approval of the Association for the Assessment and Accreditation of Laboratory Animal Care at the University of Wisconsin-Madison.

AGM Explant Culture {#sec4.2}
-------------------

AGMs were dissected from E11.5 embryos. AGMs were infected (see below) and cultured as described by [@bib16]. Intact AGMs were cultured for 4 days on Durapore filters (Millipore) at the air-liquid interface in IMDM^+^ (Iscove\'s modified Dulbecco\'s medium) (Gibco) supplemented with 20% fetal bovine serum (FBS; Gemini), 4 mM L-glutamine (Gibco), 1% penicillin/streptomycin (Cellgro), 0.1 mM mercaptoethanol, 100 ng/ml interleukin-3 (R&D Systems), 100 ng/ml Flt3L (R&D), and 1.5% conditioned medium from a Kit ligand-producing Chinese hamster ovary cell line.

Retroviral Infection {#sec4.3}
--------------------

Detailed methodology is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}. *Gpr65* shRNA were cloned into the MSCV-PIG (IRES-GFP) vector (kindly provided by Dr. Mitchell Weiss) ([@bib45]) using BglII and XhoI restriction sites. Retroviral expression vectors for *Gata2* and shLuc were described by [@bib31]. Retroviruses were packaged by co-transfecting 293T cells with pCL-Eco packaging vector. Retroviral supernatant was collected 24 and 48 hr post transfection and centrifuged to remove cells and debris. The Retro-X Concentrator (Clontech \#631455) was used to concentrate retrovirus. E11.5 AGMs were infected with 20 μl concentrated retrovirus and 8 μg/ml polybrene in 500 μl explant culture media at 1,200 × *g* for 90 min at 30°C. AGMs were subjected to explant culture. Primary erythroid precursors were spinfected with 100 μl retrovirus supernatant and 8 μg/ml polybrene in 400 μl fetal liver expansion medium at 1,200 × *g* for 90 min at 30°C. After centrifugation, 500 μl pre-warmed fetal liver expansion medium was added, and cells were incubated at 37°C for 72 hr. Details for concentrating retrovirus and *Gpr65* shRNA sequences are available in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Flow Cytometry {#sec4.4}
--------------

Detailed methodology is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

ChIP Assay {#sec4.5}
----------

Detailed methodology is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Zebrafish Morpholino Knockdown {#sec4.6}
------------------------------

Detailed methodology is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.7}
--------------------

Student\'s t tests were conducted using GraphPad Software or Microsoft Excel. p Values in all figures are denoted by asterisks: ^∗^p \< 0.05, ^∗∗^p \< .01, and ^∗∗∗^p \< .001.
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====================

All authors participated in designing experiments and/or analyzing data. J.L.L. conducted the zebrafish experiments and analyzed the data. X.G. and E.H.B. wrote the manuscript in consultation with other authors.

Accession Numbers {#app1}
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![GATA-2 Expression in +9.5^−/−^ AGM Rescues CD31^+^c-KIT^+^ Hematopoietic and CD31^+^c-KIT^−^ Endothelial Cells\
(A) AGM ex vivo retroviral infection and culture.\
(B) Flow cytometric analysis of GFP^+^ cells within total live cells (6 litters: +9.5^+/+^-Empty \[n = 8 embryos\]; +9.5^−/−^-Empty \[n = 4 embryos\]; +9.5^−/−^-GATA-2 \[n = 6 embryos\]).\
(C) RT-PCR analysis of *Gata2* mRNA levels in FACS-sorted CD31^+^c-KIT^−^ and CD31^+^c-KIT^+^ cells (six litters: +9.5^+/+^-Empty \[n = 8 embryos\]; +9.5^−/−^-Empty \[n = 4 embryos\]; +9.5^−/−^-GATA-2 \[n = 6 embryos\]).\
(D) Representative flow cytometric plots of CD31^+^c-KIT^+^ and CD31^+^c-KIT^−^ cell populations in infected AGMs after 96 hr of ex vivo culture.\
(E and F) Quantitation of flow cytometry data expressed as percentage of CD31^+^c-KIT^−^ and CD31^+^c-KIT^+^ cells in GFP^+^ cells (E) and the percentage of GFP^+^ cells in CD31^+^c-KIT^−^ and CD31^+^c-KIT^+^ cells (F) (6 litters: +9.5^+/+^-Empty \[n = 8 embryos\]; +9.5^−/−^-Empty \[n = 4 embryos\]; +9.5^−/−^-GATA-2 \[n = 6 embryos\]).\
Error bars represent SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (two-tailed unpaired Student\'s t test).](gr1){#fig1}

![Rescued CD31^+^c-KIT^+^ Cells Exhibit Normal Colony-Forming Unit Activity\
(A and B) Quantitative analysis of colony-forming activity of FACS-sorted CD31^+^c-KIT^+^ cells (6 litters: +9.5^+/+^-Empty \[n = 9 embryos\]; +9.5^−/−^-Empty \[n = 7 embryos\]; +9.5^−/−^-GATA-2 \[n = 10 embryos\]).\
(C) Representative BFU-E, CFU-GM, and CFU-GEMM colonies from FACS-sorted CD31^+^c-KIT^+^ cells. Scale bar, 2 mm.\
(D) Representative images of Wright-Giemsa-stained cells from colonies. Ery, erythroblast; Mac, macrophage; My, myeloid precursor; Neu, neutrophil. Scale bar, 40 μm.\
Error bars represent SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (two-tailed unpaired Student\'s t test).](gr2){#fig2}

![Global GPCR Analysis in the AGM\
(A) Global GPCR analysis.\
(B) Non-olfactory GPCRs (N = 314) were categorized into Secretin, Adhesion, Glutamate, Frizzled/Taste2, and Rhodopsin families based on sequence homology.\
(C) Classification of 85 GPCRs expressed in the AGM (\>5 transcripts per million) into five families.\
(D) Bar graph depicting GATA-2-regulated genes from RNA-seq analysis of +9.5^+/+^ and +9.5^−/−^ AGMs ([@bib16]). Black bars, genes co-regulated by GATA-1 according to our prior microarray analysis of G1E-ER-GATA with or without β-estradiol treatment ([@bib12]).\
(E) *Gata2, Adora3, Gpr65, Ltb4r1,* and *P2ry1* expression during erythropoiesis. B, basophilic erythroblast; O, polyorthochromatic erythroblast; P, proerythroblast; R, reticulocyte (<http://www.cbil.upenn.edu/ErythronDB/>).\
(F) Time course of *Gata2* and *Gpr65* expression following β-estradiol treatment in G1E-ER-GATA cells (n = 3 independent experiments).\
(G) RT-PCR analysis of *Gata2* and *Gpr65* in FACS-sorted R1, R2, R3, and R4/5 populations from fetal liver (n = 3 independent experiments).\
(H and I) ChIP signal map for *Gpr65* in human CD34 cells (H) ([@bib4]), mouse HPC7 cells ([@bib67]), Lin^−^ bone marrow cells ([@bib35]), and G1E cells ([@bib63]) (I).\
(J and K) RT-PCR analysis of *Gata2* and *Gpr65* mRNA in +9.5^+/+^ and +9.5^−/−^ AGM (5 litters: +9.5^+/+^ \[n = 8 embryos\]; +9.5^−/−^ \[n = 6 embryos\]) and yolk sac (three litters: +9.5^+/+^ \[n = 7 embryos\]; +9.5^−/−^ \[n = 5 embryos\]) (J), and MAE cells expressing GATA-2 (K) (n = 3 independent experiments).\
(L) RNA-seq of *Gata2* and *Gpr65* mRNA in FACS-sorted endothelial cells (EC), hemogenic endothelial cells (HEC), hematopoietic cells (HC), and hematopoietic stem cells (HSC) from the AGM ([@bib59]).\
Error bars represent SEM. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001 (two-tailed unpaired Student\'s t test).](gr3){#fig3}

![GPR65 Suppresses Hematopoiesis in the Mouse and Zebrafish AGM\
(A) Representative flow cytometric plots of CD31^+^c-KIT^+^ and CD31^+^c-KIT^+^SCA1^+^ cell populations in control or *Gpr65* shRNA-treated AGMs after 96 hr of culture.\
(B) Quantitation of GFP^+^ cells with total live cells (9 litters: shLuc \[n = 22 embryos\]; sh*Gpr65* \[n = 26 embryos\]).\
(C) RT-PCR analysis of *Gpr65* mRNA levels in FACS-sorted GFP^+^ cells (6 litters: shLuc \[n = 15 embryos\]; sh*Gpr65* \[n = 15 embryos\]).\
(D and E) Analysis of flow cytometry data expressed as percentage of CD31^+^c-KIT^+^ (D) and CD31^+^c-KIT^+^Scal1^+^ (E) cells in GFP^+^ cells (D: 9 litters: shLuc \[n = 22 embryos\]; sh*Gpr65* \[n = 26 embryos\]; E: 7 litters: shLuc \[n = 18\]; sh*Gpr65* \[n = 22\]).\
(F) Representative images of ISH with the HSPC markers *Runx1/cMyb* at 36 hr post-fertilization.\
(G) Quantitation of ISH data expressed as percentage of embryos with high, medium, and low *Runx1/cMyb* staining in total embryos (ATG MO 0 ng \[124 embryos\]; ATG MO 4 ng \[75 embryos\]; ATG MO 6 ng \[66 embryos\]; SP MO 0 ng \[97 embryos\]; SP MO 4 ng \[49 embryos\]; SP MO 6 ng \[58 embryos\]). *Gpr65*\_ATG MO: morpholino targeting the translation start site of *Gpr65*; *Gpr65*\_SP MO: morpholino blocking the splicing of *Gpr65*.\
Error bars represent SEM. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001 (two-tailed unpaired Student\'s t test).](gr4){#fig4}

![Psychosine Promotes Hematopoiesis in the AGM and GPR65 Suppresses Hematopoiesis by Repressing *Gata2* Expression\
(A) Representative flow cytometric plots of CD31^+^c-KIT^+^ and CD31^+^c-KIT^+^SCA1^+^ cell populations in the AGM after 4 days of culture with 20 μM psychosine.\
(B and C) The average percentage of CD31^+^c-KIT^+^ (B) and CD31^+^c-KIT^+^SCA1^+^ (C) cell populations with vehicle or psychosine treatment (6 litters: control \[n = 19 embryos\]; psychosine \[n = 20 embryos\]).\
(D and E) RT-PCR analysis of *Gpr65, Gata2,* and *Runx1* mRNA (D) and *Gata2* primary transcript (E) in FACS-sorted CD31^+^c-KIT^−^ cells (n = 3 independent experiments).\
Error bars represent SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (two-tailed unpaired Student\'s t test).](gr5){#fig5}

![GPR65 Enhances H4K20me1 and Limits Scl/TAL1 Occupancy at the +9.5 Enhancer\
(A) Representative flow cytometric plots of erythroid maturation based on CD71 and Ter119 expression 3 days after HSPC expansion. The average percentage of cells in R1 through R5 populations after infection with control or *Gpr65* shRNA is depicted on the right (n = 3 independent experiments).\
(B) RT-PCR analysis of *Gpr65* mRNA in fetal liver cells (n = 5 independent experiments) (left). Western blot of GPR65 in fetal liver cells (top right), and quantification of GPR65 and α-tubulin intensities by densitometry (n = 8 independent experiments) (bottom right).\
(C) RT-PCR analysis of *Gata2* mRNA and primary transcript in total fetal liver cells (n = 5 independent experiments).\
(D) Western blot of GATA-2 in fetal liver cells (top) and quantification of GATA-2/α-tubulin ratio by densitometry (n = 6 independent experiments) (bottom).\
(E) RT-PCR analysis of GATA-2 target gene expression in fetal liver cells (n = 5 independent experiments).\
(F--I) Real-time RT-PCR analysis of *Gpr65* mRNA (F), *Gata2* mRNA (G), *Gata2* primary transcript (G), and GATA-2 target genes in FACS-sorted R2 cells (n = 3 independent experiments) (I). Western blot of GATA-2 in FACS-sorted R2 cells and quantification of intensities of GATA-2 to α-tubulin band by densitometric analysis (n = 4 independent experiments) (H).\
(J) Fetal liver HSPCs were isolated from E14.5 embryos heterozygous for the +9.5 site at *Gata2*. Cells were infected with control or sh*Gpr65* and expanded for 3 days (left). Allele-specific real-time RT-PCR analysis of *Gata2* transcripts from the wild-type and mutant +9.5 alleles in total fetal liver cells (n = 3 independent experiments) (middle) and FACS-sorted R2 cells (n = 3 independent experiments) (right).\
(K) RT-PCR analysis of *Setd8* mRNA in fetal liver cells treated with control or *Gpr65* shRNA (n = 5 independent experiments) (top left). H4K20me1, GATA-1, and Scl/TAL1 chromatin occupancy measured by quantitative ChIP at the +9.5 site in expanding fetal liver HSPCs treated with control or *Gpr65* shRNA (H4K20me1: n = 8 independent experiments; GATA-1: n = 4 independent experiments; Scl/TAL1: n = 6 independent experiments) (right). H4K20me1 levels at the repressed MyoD promoter and the active *Eif3k* promoter (middle left). Scl/TAL1 chromatin occupancy 114 kb upstream from the *c-Kit* promoter and Lyl1 exon1 as controls (bottom left). The dashed line illustrates the highest value obtained with PI antibody.\
(L) GATA-2, a positive regulator of hematopoiesis, upregulates *Gpr65,* which encodes a negative regulator of hematopoiesis, to control HSC emergence. GPR65 represses *Gata2* expression by increasing H4K20me1, which restricts +9.5 occupancy by the activator Scl/TAL1.\
Error bars represent SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (two-tailed unpaired Student\'s t test).](gr6){#fig6}
